Idorsia announces executive changes as CEO to retire

Swiss biotech Idorsia (SIX: IDIA) today announced changes to its executive committee (IEC) and will propose changes in membership of the board of directors at the upcoming annual general meeting of shareholders (AGM), to be held on June 13, 2024.

Jean-Paul Clozel, 69, has decided to retire from his role as chief executive (CEO) of Idorsia and stand for election as chairman of the board of directors at this year’s AGM. He has served as CEO of Idorsia since its foundation – the result of demerging the drug discovery and early clinical pipeline of Actelion, as part of the $30 billion acquisition by Johnson & Johnson (NYSE: JNJ). Dr Clozel had previously co-founded Actelion in 1997 and went on to lead the company as CEO in 2000 when the company became publicly traded.

From June 13, 2024, André Muller will take on the position of CEO. Mr Muller has served as the chief financial officer (CFO) of Idorsia since its foundation and has taken the lead in the company’s business development initiatives in recent years. Before establishing Idorsia, he served as CFO of Actelion from 2013, leading the company through its acquisition and playing a crucial role in the demerger process.